To assess the benefit and safety of composite therapy (Tamsulosin and Trospium drugs) in treating benign prostatic enlargement complain, mainly overactive urinary bladder symptoms. OBJECTIVE: The study has been designed to estimate the benefit and safety of Trospium and Tamsulosin in processing of symptoms of excessive bladder and benign prostate hyperplasia (BPH). Patients and Methods: Prospective clinical trial study conducted at Al-Diwaniya teaching hospitals and private clinics from march 2016 to march 2017, to patients BPH and bothersome symptoms. 60 patients were treated with Tamsulocin and 60 patients were treated by Tamsulocin and Trospium. RESULTS: Median scores of IPSS, OABSS, and QOL proved no big difference between two study sets before staring treatment (P = 0.544), (P = 0.287) , (P = 0.668) consecutively. After one month, both treatments led to a big reduction in IPSS, OABSS median score; (P < 0.001), (P < 0.001). Following three months, both treatments resulted in significant reduction in IPSS (P < 0.001), OABSS (P < 0.001), QOL result, (P < 0.001) consecutively. Conclusion: These results suggest which treatment with Trospium and tamsulosin therapy provides benefit for men with natural - Syndrome of the acute urinary tract and benign enlarged prostate.
Role of Trospium chloride and tamsulosin therapy for treating patients with symptoms of over-active bladder related to benign prostatic enlargement